Overexpression of OASL upregulates TET1 to induce aberrant activation of CD4+ T cells in systemic sclerosis via IRF1 signaling

Table 1 The clinical features of patients

Patients	Gender	Age	Antibody	Disease duration	Therapy	mRSS	IDF	Digestive tract involvement
1	Male	49	ATA	2 years	None	36	1	1
2	Female	35	ATA	4 years	None	40	1	1
3	Female	48	ATA	1 year	None	27	1	0
4	Female	49	ATA	1 year	None	35	1	0
5	Female	56	ATA	3 years	None	41	0	1
6	Female	36	ATA	9 months	None	38	1	0
7	Female	60	ATA	2 years	None	22	1	0
8	Female	59	ATA	5 months	None	25	1	0
9	Female	36	ATA	1 year	None	20	0	1
10	Male	27	ATA	6 months	None	29	0	0
11	Male	61	ATA	3 years	None	30	1	1
12	Female	58	ATA	1 year	None	28	1	0
13	Female	55	ATA	5 years	None	32	1	1
14	Male	25	ATA¹	8 months	None	15	0	0
15	Male	60	ATA	4 years	None	31	0	1

ATA anti-scl70 antibody positive, Therapy immunosuppressive therapy or glucocorticoid therapy, mRSS modified Rodnan skin score, IDF idiopathic pulmonary fibrosis; 1: yes; 0: No
No.1–5 patients were selected for RNA-seq

ISSN: 1478-6362